{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:33:43Z","timestamp":1788636823181,"version":"build-2803163510"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["945118"],"award-info":[{"award-number":["945118"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Basic Res Cardiol"],"DOI":"10.1007\/s00395-024-01078-6","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T07:02:29Z","timestamp":1725865349000},"page":"71-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cardioprotection strategies for anthracycline cardiotoxicity"],"prefix":"10.1007","volume":"120","author":[{"given":"Andrea","family":"Moreno-Arciniegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"C\u00e1diz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gal\u00e1n-Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Clemente-Morag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5036-254X","authenticated-orcid":false,"given":"Borja","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"1078_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.018393","author":"H Abdel-Qadir","year":"2021","unstructured":"Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Arguelles O, Amir E, Lee DS, Thavendiranathan P (2021) Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.119.018393","journal-title":"J Am Heart Assoc"},{"key":"1078_CR2","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41598-018-37862-3","volume":"9","author":"CS Abdullah","year":"2019","unstructured":"Abdullah CS, Alam S, Aishwarya R, Miriyala S, Bhuiyan MAN, Panchatcharam M, Pattillo CB, Orr AW, Sadoshima J, Hill JA, Bhuiyan MS (2019) Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Sci Rep 9:2002","journal-title":"Sci Rep"},{"key":"1078_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110028","author":"N Ahmad","year":"2022","unstructured":"Ahmad N, Ullah A, Chu P, Tian W, Tang Z, Sun Z (2022) Doxorubicin induced cardio toxicity through sirtuins mediated mitochondrial disruption. Chem Biol Interact. https:\/\/doi.org\/10.1016\/j.cbi.2022.110028","journal-title":"Chem Biol Interact"},{"key":"1078_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2015","unstructured":"Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A (2015) Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17:81\u201389. https:\/\/doi.org\/10.1002\/ejhf.196","journal-title":"Eur J Heart Fail"},{"key":"1078_CR5","doi-asserted-by":"publisher","first-page":"9388","DOI":"10.26355\/eurrev_202310_33966","volume":"27","author":"AH Alhowail","year":"2023","unstructured":"Alhowail AH (2023) Pioglitazone ameliorates doxorubicin-induced hypothyroidism and cardiotoxicity in rat models. Eur Rev Med Pharmacol Sci 27:9388\u20139395. https:\/\/doi.org\/10.26355\/eurrev_202310_33966","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1078_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.abb.2018.01.004","volume":"640","author":"Y Aratani","year":"2018","unstructured":"Aratani Y (2018) Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys 640:47\u201352. https:\/\/doi.org\/10.1016\/j.abb.2018.01.004","journal-title":"Arch Biochem Biophys"},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Das Dores Cruz F, Goncalves Brandao SM, Rigaud VOC, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA (2018) Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 71:2281\u20132290. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049","journal-title":"J Am Coll Cardiol"},{"key":"1078_CR8","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1042\/BCJ20160385","volume":"473","author":"JJ Bartlett","year":"2016","unstructured":"Bartlett JJ, Trivedi PC, Yeung P, Kienesberger PC, Pulinilkunnil T (2016) Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy. Biochem J 473:3769\u20133789. https:\/\/doi.org\/10.1042\/BCJ20160385","journal-title":"Biochem J"},{"key":"1078_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40959-023-00161-6","volume":"9","author":"MMC Becker","year":"2023","unstructured":"Becker MMC, Arruda GFA, Berenguer DRF, Buril RO, Cardinale D, Brandao SCS (2023) Anthracycline cardiotoxicity: current methods of diagnosis and possible role of (18)F-FDG PET\/CT as a new biomarker. Cardiooncology 9:17. https:\/\/doi.org\/10.1186\/s40959-023-00161-6","journal-title":"Cardiooncology"},{"key":"1078_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00395-022-00947-2","volume":"117","author":"RM Bell","year":"2022","unstructured":"Bell RM, Basalay M, Botker HE, Beikoghli Kalkhoran S, Carr RD, Cunningham J, Davidson SM, England TJ, Giesz S, Ghosh AK, Golforoush P, Gourine AV, Hausenloy DJ, Heusch G, Ibanez B, Kleinbongard P, Lecour S, Lukhna K, Ntsekhe M, Ovize M, Salama AD, Vilahur G, Walker JM, Yellon DM (2022) Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop. Basic Res Cardiol 117:39. https:\/\/doi.org\/10.1007\/s00395-022-00947-2","journal-title":"Basic Res Cardiol"},{"key":"1078_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.947604","author":"A Bhagat","year":"2022","unstructured":"Bhagat A, Shrestha P, Jeyabal P, Peng Z, Watowich SS, Kleinerman ES (2022) Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.947604","journal-title":"Front Oncol"},{"key":"1078_CR12","doi-asserted-by":"publisher","first-page":"H702","DOI":"10.1152\/ajpheart.00231.2022","volume":"323","author":"JC Bikomeye","year":"2022","unstructured":"Bikomeye JC, Terwoord JD, Santos JH, Beyer AM (2022) Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress. Am J Physiol Heart Circ Physiol 323:H702\u2013H720. https:\/\/doi.org\/10.1152\/ajpheart.00231.2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1078_CR13","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzo M, Esteve J (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61:2355\u20132362. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.072","journal-title":"J Am Coll Cardiol"},{"key":"1078_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00395-018-0696-8","volume":"113","author":"HE Botker","year":"2018","unstructured":"Botker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femmino S, Garcia-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhauser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schluter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G (2018) Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 113:39. https:\/\/doi.org\/10.1007\/s00395-018-0696-8","journal-title":"Basic Res Cardiol"},{"issue":"487","key":"1078_CR15","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/j.ahj.2010.05.037","volume":"160","author":"C Cadeddu","year":"2010","unstructured":"Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, Massa E, Mercuro G (2010) Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160(487):e481-487. https:\/\/doi.org\/10.1016\/j.ahj.2010.05.037","journal-title":"Am Heart J"},{"key":"1078_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"D Cardinale","year":"2018","unstructured":"Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM, Investigators I-OS (2018) Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur J Cancer 94:126\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.005","journal-title":"Eur J Cancer"},{"key":"1078_CR17","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981\u20131988. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013777","journal-title":"Circulation"},{"key":"1078_CR18","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474\u20132481. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.635144","journal-title":"Circulation"},{"key":"1078_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jaccao.2022.11.020","volume":"5","author":"YF Cheung","year":"2023","unstructured":"Cheung YF, Li VW, So EK, Cheng FW, Yau JP, Chiu SY, Wong WH, Cheuk DK (2023) Remote ischemic conditioning in pediatric cancer patients receiving anthracycline chemotherapy: a sham-controlled single-blind randomized trial. JACC CardioOncol 5:332\u2013342. https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.020","journal-title":"JACC CardioOncol"},{"key":"1078_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rehab.2021.101485","author":"WP Chung","year":"2022","unstructured":"Chung WP, Yang HL, Hsu YT, Hung CH, Liu PY, Liu YW, Chan SH, Tsai KL (2022) Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: a randomized controlled trial. Ann Phys Rehabil Med. https:\/\/doi.org\/10.1016\/j.rehab.2021.101485","journal-title":"Ann Phys Rehabil Med"},{"key":"1078_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014638.pub2","author":"EC de Baat","year":"2022","unstructured":"de Baat EC, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM, Mavinkurve-Groothuis AM, Kremer LC, van Dalen EC (2022) Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD014638.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1078_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaccao.2024.02.005","volume":"6","author":"A Diaz-Guerra","year":"2024","unstructured":"Diaz-Guerra A, Villena-Gutierrez R, Clemente-Moragon A, Gomez M, Oliver E, Fernandez-Tocino M, Galan-Arriola C, Cadiz L, Ibanez B (2024) Anthracycline cardiotoxicity induces progressive changes in myocardial metabolism and mitochondrial quality control: novel therapeutic target. JACC CardioOncol 6:217\u2013232. https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.005","journal-title":"JACC CardioOncol"},{"key":"1078_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01046-0","author":"P Efentakis","year":"2024","unstructured":"Efentakis P, Choustoulaki A, Kwiatkowski G, Varela A, Kostopoulos IV, Tsekenis G, Ntanasis-Stathopoulos I, Georgoulis A, Vorgias CE, Gakiopoulou H, Briasoulis A, Davos CH, Kostomitsopoulos N, Tsitsilonis O, Dimopoulos MA, Terpos E, Chlopicki S, Gavriatopoulou M, Andreadou I (2024) Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin. Basic Res Cardiol. https:\/\/doi.org\/10.1007\/s00395-024-01046-0","journal-title":"Basic Res Cardiol"},{"key":"1078_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.tox.2017.08.011","volume":"390","author":"A Ferreira","year":"2017","unstructured":"Ferreira A, Cunha-Oliveira T, Simoes RF, Carvalho FS, Burgeiro A, Nordgren K, Wallace KB, Oliveira PJ (2017) Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity. Toxicology 390:63\u201373. https:\/\/doi.org\/10.1016\/j.tox.2017.08.011","journal-title":"Toxicology"},{"key":"1078_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s10334-020-00848-2","author":"T Ferreira da Silva","year":"2020","unstructured":"Ferreira da Silva T, Galan-Arriola C, Montesinos P, Lopez-Martin GJ, Desco M, Fuster V, Ibanez B, Sanchez-Gonzalez J (2020) Single breath-hold saturation recovery 3D cardiac T1 mapping via compressed SENSE at 3T. MAGMA. https:\/\/doi.org\/10.1007\/s10334-020-00848-2","journal-title":"MAGMA"},{"key":"1078_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/CIRCULATIONAHA.122.062814","volume":"147","author":"SJ Foulkes","year":"2023","unstructured":"Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, Loi S, Claus P, Janssens K, Mitchell AM, Wright L, Costello BT, Lindqvist A, Burnham L, Wallace I, Daly RM, Fraser SF, La Gerche A (2023) Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study. Circulation 147:532\u2013545. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062814","journal-title":"Circulation"},{"key":"1078_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40360-021-00495-w","volume":"22","author":"T Furihata","year":"2021","unstructured":"Furihata T, Maekawa S, Takada S, Kakutani N, Nambu H, Shirakawa R, Yokota T, Kinugawa S (2021) Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice. BMC Pharmacol Toxicol 22:27. https:\/\/doi.org\/10.1186\/s40360-021-00495-w","journal-title":"BMC Pharmacol Toxicol"},{"key":"1078_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","volume":"73","author":"C Galan-Arriola","year":"2019","unstructured":"Galan-Arriola C, Lobo M, Vilchez-Tschischke JP, Lopez GJ, de Molina-Iracheta A, Perez-Martinez C, Aguero J, Fernandez-Jimenez R, Martin-Garcia A, Oliver E, Villena-Gutierrez R, Pizarro G, Sanchez PL, Fuster V, Sanchez-Gonzalez J, Ibanez B (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73:779\u2013791. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.046","journal-title":"J Am Coll Cardiol"},{"key":"1078_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab053","author":"C Galan-Arriola","year":"2021","unstructured":"Galan-Arriola C, Vilchez-Tschischke JP, Lobo M, Lopez GJ, de Molina-Iracheta A, Perez-Martinez C, Villena-Gutierrez R, Macias A, Diaz-Rengifo IA, Oliver E, Fuster V, Sanchez-Gonzalez J, Ibanez B (2021) Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvab053","journal-title":"Cardiovasc Res"},{"key":"1078_CR30","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/cvr\/cvaa181","volume":"117","author":"C Galan-Arriola","year":"2021","unstructured":"Galan-Arriola C, Villena-Gutierrez R, Higuero-Verdejo MI, Diaz-Rengifo IA, Pizarro G, Lopez GJ, Molina-Iracheta A, Perez-Martinez C, Garcia RD, Gonzalez-Calle D, Lobo M, Sanchez PL, Oliver E, Cordoba R, Fuster V, Sanchez-Gonzalez J, Ibanez B (2021) Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovasc Res 117:1132\u20131143. https:\/\/doi.org\/10.1093\/cvr\/cvaa181","journal-title":"Cardiovasc Res"},{"key":"1078_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fphar.2014.00025","volume":"5","author":"E Gammella","year":"2014","unstructured":"Gammella E, Maccarinelli F, Buratti P, Recalcati S, Cairo G (2014) The role of iron in anthracycline cardiotoxicity. Front Pharmacol 5:25. https:\/\/doi.org\/10.3389\/fphar.2014.00025","journal-title":"Front Pharmacol"},{"key":"1078_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/life11111123","author":"WR Garcia-Nino","year":"2021","unstructured":"Garcia-Nino WR, Zazueta C, Buelna-Chontal M, Silva-Palacios A (2021) Mitochondrial quality control in cardiac-conditioning strategies against ischemia-reperfusion injury. Life (Basel). https:\/\/doi.org\/10.3390\/life11111123","journal-title":"Life (Basel)"},{"key":"1078_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jaccao.2019.11.004","volume":"1","author":"ZM Gertz","year":"2019","unstructured":"Gertz ZM, Cain C, Kraskauskas D, Devarakonda T, Mauro AG, Thompson J, Samidurai A, Chen Q, Gordon SW, Lesnefsky EJ, Das A, Salloum FN (2019) Remote ischemic pre-conditioning attenuates adverse cardiac remodeling and mortality following doxorubicin administration in mice. JACC CardioOncol 1:221\u2013234. https:\/\/doi.org\/10.1016\/j.jaccao.2019.11.004","journal-title":"JACC CardioOncol"},{"key":"1078_CR34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.20517\/cdr.2021.65","volume":"4","author":"WH Gmeiner","year":"2021","unstructured":"Gmeiner WH, van Waardenburg R (2021) Targeting DNA topoisomerases: past and future. Cancer Drug Resist 4:758\u2013761. https:\/\/doi.org\/10.20517\/cdr.2021.65","journal-title":"Cancer Drug Resist"},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jcmg.2021.02.031","volume":"14","author":"S Gomez-Talavera","year":"2021","unstructured":"Gomez-Talavera S, Fernandez-Jimenez R, Fuster V, Nothnagel ND, Kouwenhoven M, Clemence M, Garcia-Lunar I, Gomez-Rubin MC, Navarro F, Perez-Asenjo B, Fernandez-Friera L, Calero MJ, Orejas M, Cabrera JA, Desco M, Pizarro G, Ibanez B, Sanchez-Gonzalez J (2021) Clinical validation of a 3-dimensional ultrafast cardiac magnetic resonance protocol including single breath-hold 3-dimensional sequences. JACC Cardiovasc Imaging 14:1742\u20131754. https:\/\/doi.org\/10.1016\/j.jcmg.2021.02.031","journal-title":"JACC Cardiovasc Imaging"},{"key":"1078_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","volume":"10","author":"CA Gongora","year":"2022","unstructured":"Gongora CA, Drobni ZD, Quinagliaaraujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, Gilman HK, Hartmann SE, Sama S, Nikolaidou S, Suero-Abreu GA, Jacobsen E, Abramson JS, Hochberg E, Barnes J, Armand P, Thavendiranathan P, Nohria A, Neilan TG (2022) Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail 10:559\u2013567. https:\/\/doi.org\/10.1016\/j.jchf.2022.03.006","journal-title":"JACC Heart Fail"},{"key":"1078_CR37","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671\u20131680. https:\/\/doi.org\/10.1093\/eurheartj\/ehw022","journal-title":"Eur Heart J"},{"key":"1078_CR38","doi-asserted-by":"publisher","first-page":"153473541984399","DOI":"10.1177\/1534735419843999","volume":"18","author":"SE Hall","year":"2019","unstructured":"Hall SE, Smuder AJ, Hayward R (2019) Effects of calorie restriction and voluntary exercise on doxorubicin-induced cardiotoxicity. Integr Cancer Ther 18:1534735419843999. https:\/\/doi.org\/10.1177\/1534735419843999","journal-title":"Integr Cancer Ther"},{"key":"1078_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12012-020-09626-x","volume":"21","author":"L He","year":"2021","unstructured":"He L, Liu F, Li J (2021) Mitochondrial sirtuins and doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol 21:179\u2013191. https:\/\/doi.org\/10.1007\/s12012-020-09626-x","journal-title":"Cardiovasc Toxicol"},{"key":"1078_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaccao.2020.01.005","volume":"2","author":"Q He","year":"2020","unstructured":"He Q, Wang F, Ryan TD, Chalasani M, Redington AN (2020) Repeated remote ischemic conditioning reduces doxorubicin-induced cardiotoxicity. JACC CardioOncol 2:41\u201352. https:\/\/doi.org\/10.1016\/j.jaccao.2020.01.005","journal-title":"JACC CardioOncol"},{"key":"1078_CR41","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Rosjo H, Steine K, Geisler J, Gulati G, Omland T (2021) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation 143:2431\u20132440. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054698","journal-title":"Circulation"},{"key":"1078_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102894","author":"G Heusch","year":"2023","unstructured":"Heusch G, Andreadou I, Bell R, Bertero E, Botker HE, Davidson SM, Downey J, Eaton P, Ferdinandy P, Gersh BJ, Giacca M, Hausenloy DJ, Ibanez B, Krieg T, Maack C, Schulz R, Sellke F, Shah AM, Thiele H, Yellon DM, Di Lisa F (2023) Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection. Redox Biol. https:\/\/doi.org\/10.1016\/j.redox.2023.102894","journal-title":"Redox Biol"},{"key":"1078_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jacc.2014.10.031","volume":"65","author":"G Heusch","year":"2015","unstructured":"Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D (2015) Remote ischemic conditioning. J Am Coll Cardiol 65:177\u2013195. https:\/\/doi.org\/10.1016\/j.jacc.2014.10.031","journal-title":"J Am Coll Cardiol"},{"key":"1078_CR44","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/cvr\/cvaa199","volume":"117","author":"G Heusch","year":"2021","unstructured":"Heusch G, Rassaf T (2021) Protection from cardiotoxicity of cancer chemotherapy: a novel target for remote ischaemic conditioning? Cardiovasc Res 117:985\u2013986. https:\/\/doi.org\/10.1093\/cvr\/cvaa199","journal-title":"Cardiovasc Res"},{"key":"1078_CR45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/2047487318811181","volume":"26","author":"EJ Howden","year":"2019","unstructured":"Howden EJ, Bigaran A, Beaudry R, Fraser S, Selig S, Foulkes S, Antill Y, Nightingale S, Loi S, Haykowsky MJ, La Gerche A (2019) Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. Eur J Prev Cardiol 26:305\u2013315. https:\/\/doi.org\/10.1177\/2047487318811181","journal-title":"Eur J Prev Cardiol"},{"key":"1078_CR46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","volume":"24","author":"S Huang","year":"2019","unstructured":"Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, Shen MT, Fu H, Guo YK (2019) Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Heart Fail Rev 24:325\u2013333. https:\/\/doi.org\/10.1007\/s10741-018-9755-3","journal-title":"Heart Fail Rev"},{"key":"1078_CR47","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200097","author":"WG Hundley","year":"2022","unstructured":"Hundley WG, D\u2019Agostino R Jr, Crotts T, Craver K, Hackney MH, Jordan JH, Ky B, Wagner LI, Herrington DM, Yeboah J, Reding KW, Ladd AC, Rapp SR, Russo S, O\u2019Connell N, Weaver KE, Dressler EV, Ge Y, Melin SA, Gudena V, Lesser GJ (2022) Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evid. https:\/\/doi.org\/10.1056\/evidoa2200097","journal-title":"NEJM Evid"},{"key":"1078_CR48","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jacc.2019.05.024","volume":"74","author":"B Ibanez","year":"2019","unstructured":"Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, Bucciarelli-Ducci C, Croisille P, Dall\u2019Armellina E, Dharmakumar R, Eitel I, Fernandez-Jimenez R, Friedrich MG, Garcia-Dorado D, Hausenloy DJ, Kim RJ, Kozerke S, Kramer CM, Salerno M, Sanchez-Gonzalez J, Sanz J, Fuster V (2019) Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. J Am Coll Cardiol 74:238\u2013256. https:\/\/doi.org\/10.1016\/j.jacc.2019.05.024","journal-title":"J Am Coll Cardiol"},{"key":"1078_CR49","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jaccao.2023.05.002","volume":"5","author":"B Ibanez","year":"2023","unstructured":"Ibanez B, Gomes-Silva M (2023) Remote ischemic conditioning for anthracycline cardiotoxicity: the need to protect the most vulnerable. JACC CardioOncol 5:356\u2013359. https:\/\/doi.org\/10.1016\/j.jaccao.2023.05.002","journal-title":"JACC CardioOncol"},{"key":"1078_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jacbts.2021.11.010","volume":"7","author":"B Ibanez","year":"2022","unstructured":"Ibanez B, Moreno-Arciniegas A (2022) The quest for an early marker of anthracycline-induced cardiotoxicity. JACC Basic Transl Sci 7:11\u201313. https:\/\/doi.org\/10.1016\/j.jacbts.2021.11.010","journal-title":"JACC Basic Transl Sci"},{"key":"1078_CR51","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jacc.2021.01.017","volume":"77","author":"B Ibanez","year":"2021","unstructured":"Ibanez B, Villena-Gutierrez R (2021) Cardiac mitochondrial transplantation: the force awakens. J Am Coll Cardiol 77:1089\u20131092. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.017","journal-title":"J Am Coll Cardiol"},{"key":"1078_CR52","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/FJC.0000000000000891","volume":"76","author":"C Kalliora","year":"2020","unstructured":"Kalliora C, Drosatos K (2020) The glitazars paradox: cardiotoxicity of the metabolically beneficial dual PPARalpha and PPARgamma activation. J Cardiovasc Pharmacol 76:514\u2013526. https:\/\/doi.org\/10.1097\/FJC.0000000000000891","journal-title":"J Cardiovasc Pharmacol"},{"key":"1078_CR53","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-017-4554-4","volume":"167","author":"AA Kirkham","year":"2018","unstructured":"Kirkham AA, Eves ND, Shave RE, Bland KA, Bovard J, Gelmon KA, Virani SA, McKenzie DC, Stohr EJ, Waburton DER, Campbell KL (2018) The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT. Breast Cancer Res Treat 167:719\u2013729. https:\/\/doi.org\/10.1007\/s10549-017-4554-4","journal-title":"Breast Cancer Res Treat"},{"key":"1078_CR54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00395-023-01003-3","volume":"118","author":"P Kleinbongard","year":"2023","unstructured":"Kleinbongard P (2023) Perspective: mitochondrial STAT3 in cardioprotection. Basic Res Cardiol 118:32. https:\/\/doi.org\/10.1007\/s00395-023-01003-3","journal-title":"Basic Res Cardiol"},{"key":"1078_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-024-00658-w","author":"P Kleinbongard","year":"2024","unstructured":"Kleinbongard P, Andreadou I (2024) Is there a mitochondrial protection via remote ischemic conditioning in settings of anticancer therapy cardiotoxicity? Curr Heart Fail Rep. https:\/\/doi.org\/10.1007\/s11897-024-00658-w","journal-title":"Curr Heart Fail Rep"},{"key":"1078_CR56","doi-asserted-by":"publisher","first-page":"46663","DOI":"10.18632\/oncotarget.16944","volume":"8","author":"N Koleini","year":"2017","unstructured":"Koleini N, Kardami E (2017) Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget 8:46663\u201346680. https:\/\/doi.org\/10.18632\/oncotarget.16944","journal-title":"Oncotarget"},{"key":"1078_CR57","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jcmg.2020.10.024","volume":"14","author":"G Korosoglou","year":"2021","unstructured":"Korosoglou G, Giusca S, Montenbruck M, Patel AR, Lapinskas T, Gotze C, Zieschang V, Al-Tabatabaee S, Pieske B, Florian A, Erley J, Katus HA, Kelle S, Steen H (2021) Fast strain-encoded cardiac magnetic resonance for diagnostic classification and risk stratification of heart failure patients. JACC Cardiovasc Imaging 14:1177\u20131188. https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.024","journal-title":"JACC Cardiovasc Imaging"},{"key":"1078_CR58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fcvm.2020.00056","volume":"7","author":"H Kumari","year":"2020","unstructured":"Kumari H, Huang WH, Chan MWY (2020) Review on the role of epigenetic modifications in doxorubicin-induced cardiotoxicity. Front Cardiovasc Med 7:56. https:\/\/doi.org\/10.3389\/fcvm.2020.00056","journal-title":"Front Cardiovasc Med"},{"key":"1078_CR59","doi-asserted-by":"publisher","first-page":"8290","DOI":"10.1074\/jbc.M308033200","volume":"279","author":"CC Lim","year":"2004","unstructured":"Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, Sawyer DB (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279:8290\u20138299. https:\/\/doi.org\/10.1074\/jbc.M308033200","journal-title":"J Biol Chem"},{"key":"1078_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41514-024-00135-7","volume":"10","author":"AN Linders","year":"2024","unstructured":"Linders AN, Dias IB, Lopez Fernandez T, Tocchetti CG, Bomer N, Van der Meer P (2024) A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging. NPJ Aging 10:9. https:\/\/doi.org\/10.1038\/s41514-024-00135-7","journal-title":"NPJ Aging"},{"key":"1078_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01054-0","author":"X Liu","year":"2024","unstructured":"Liu X, Li Z (2024) The role and mechanism of epigenetics in anticancer drug-induced cardiotoxicity. Basic Res Cardiol. https:\/\/doi.org\/10.1007\/s00395-024-01054-0","journal-title":"Basic Res Cardiol"},{"key":"1078_CR62","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","volume":"7","author":"L Livi","year":"2021","unstructured":"Livi L, Barletta G, Martella F, Saieva C, Desideri I, Bacci C, Del Bene MR, Airoldi M, Amoroso D, Coltelli L, Scotti V, Becherini C, Visani L, Salvestrini V, Mariotti M, Pedani F, Bernini M, Sanchez L, Orzalesi L, Nori J, Bianchi S, Olivotto I, Meattini I (2021) Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial. JAMA Oncol 7:1544\u20131549. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3395","journal-title":"JAMA Oncol"},{"key":"1078_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01039-z","author":"D Lohr","year":"2024","unstructured":"Lohr D, Thiele A, Stahnke M, Braun VM, Klopfleisch R, Klein O, Dresen S, Landmesser U, Foryst-Ludwig A, Kintscher U, Schreiber LM, Beyhoff N (2024) Characterization of anthracycline-induced cardiotoxicity by diffusion tensor magnetic resonance imaging. Basic Res Cardiol. https:\/\/doi.org\/10.1007\/s00395-024-01039-z","journal-title":"Basic Res Cardiol"},{"key":"1078_CR64","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","volume":"128","author":"GD Lopaschuk","year":"2021","unstructured":"Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED (2021) Cardiac energy metabolism in heart failure. Circ Res 128:1487\u20131513. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318241","journal-title":"Circ Res"},{"key":"1078_CR65","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","volume":"41","author":"J Lopez-Sendon","year":"2020","unstructured":"Lopez-Sendon J, Alvarez-Ortega C, Zamora Aunon P, Buno Soto A, Lyon AR, Farmakis D, Cardinale D, Canales Albendea M, Feliu Batlle J, Rodriguez Rodriguez I, Rodriguez Fraga O, Albaladejo A, Mediavilla G, Gonzalez-Juanatey JR, Martinez Monzonis A, Gomez Prieto P, Gonzalez-Costello J, Serrano Antolin JM, Cadenas Chamorro R, Lopez Fernandez T (2020) Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 41:1720\u20131729. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa006","journal-title":"Eur Heart J"},{"key":"1078_CR66","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH (2022) ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"1078_CR67","doi-asserted-by":"publisher","first-page":"10323","DOI":"10.1007\/s00520-022-07368-w","volume":"30","author":"ZY Ma","year":"2022","unstructured":"Ma ZY, Yao SS, Shi YY, Lu NN, Cheng F (2022) Effect of aerobic exercise on cardiotoxic outcomes in women with breast cancer undergoing anthracycline or trastuzumab treatment: a systematic review and meta-analysis. Support Care Cancer 30:10323\u201310334. https:\/\/doi.org\/10.1007\/s00520-022-07368-w","journal-title":"Support Care Cancer"},{"key":"1078_CR68","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","volume":"1","author":"AVS Macedo","year":"2019","unstructured":"Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L, Costa RB, Landoni G, Nogueira-Rodrigues A, Ribeiro ALP (2019) Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncol 1:68\u201379. https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.003","journal-title":"JACC CardioOncol"},{"key":"1078_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.653648","author":"G Macnaught","year":"2021","unstructured":"Macnaught G, Oikonomidou O, Rodgers CT, Clarke W, Cooper A, McVicars H, Hayward L, Mirsadraee S, Semple S, Denvir MA (2021) Cardiac energetics before, during, and after anthracycline-based chemotherapy in breast cancer patients using (31)P magnetic resonance spectroscopy: a pilot study. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2021.653648","journal-title":"Front Cardiovasc Med"},{"key":"1078_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066252","author":"RH Maier","year":"2022","unstructured":"Maier RH, Plummer C, Kasim AS, Akhter N, Ogundimu E, Maddox J, Graham J, Stewart M, Wardley A, Haney S, Vahabi S, Oxenham H, Humphreys A, Cresti N, Verrill M, Graham R, Chang L, Hancock HC, Austin D (2022) Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT). BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2022-066252","journal-title":"BMJ Open"},{"key":"1078_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115651","author":"F Maleki","year":"2023","unstructured":"Maleki F, Rabbani S, Shirkoohi R, Rezaei M (2023) Allogeneic mitochondrial transplantation ameliorates cardiac dysfunction due to doxorubicin: an in vivo study. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2023.115651","journal-title":"Biomed Pharmacother"},{"key":"1078_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120701","author":"F Maleki","year":"2022","unstructured":"Maleki F, Salimi M, Shirkoohi R, Rezaei M (2022) Mitotherapy in doxorubicin induced cardiotoxicity: a promising strategy to reduce the complications of treatment. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2022.120701","journal-title":"Life Sci"},{"key":"1078_CR73","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaccao.2023.03.008","volume":"5","author":"M Mallouppas","year":"2023","unstructured":"Mallouppas M, Chung R, Ghosh AK, Macklin A, Yellon DM, Walker JM (2023) Anthracyclines and biomarkers of myocardial injury: the effect of remote ischemic conditioning. JACC CardioOncol 5:343\u2013355. https:\/\/doi.org\/10.1016\/j.jaccao.2023.03.008","journal-title":"JACC CardioOncol"},{"key":"1078_CR74","first-page":"345","volume":"9","author":"M Mallouppas","year":"2023","unstructured":"Mallouppas M, Chung R, Ghosh AK, Macklin A, Yellon DM, Walker JM (2023) Anthracyclines and biomarkers of myocardial injury: the effect of remote ischemic conditioning (RIC). JACC CardioOncology 9:345\u2013355","journal-title":"JACC CardioOncology"},{"key":"1078_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113480","author":"J Marinello","year":"2018","unstructured":"Marinello J, Delcuratolo M, Capranico G (2018) Anthracyclines as topoisomerase II poisons: from early studies to new perspectives. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19113480","journal-title":"Int J Mol Sci"},{"key":"1078_CR76","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.jcmg.2020.01.017","volume":"13","author":"A Martin-Garcia","year":"2020","unstructured":"Martin-Garcia A, Diaz-Pelaez E, Lopez-Corral L, Sanchez-Pablo C, Macias de Plasencia G, Galan-Arriola C, Sanchez-Gonzalez J, Cruz JJ, Ibanez B, Sanchez PL (2020) T2 mapping identifies early anthracycline-induced cardiotoxicity in elderly patients with cancer. JACC Cardiovasc Imaging 13:1630\u20131632. https:\/\/doi.org\/10.1016\/j.jcmg.2020.01.017","journal-title":"JACC Cardiovasc Imaging"},{"key":"1078_CR77","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00395-020-0788-0","volume":"115","author":"J Martinez-Milla","year":"2020","unstructured":"Martinez-Milla J, Galan-Arriola C, Carnero M, Cobiella J, Perez-Camargo D, Bautista-Hernandez V, Rigol M, Solanes N, Villena-Gutierrez R, Lobo M, Mateo J, Vilchez-Tschischke JP, Salinas B, Cusso L, Lopez GJ, Fuster V, Desco M, Sanchez-Gonzalez J, Ibanez B (2020) Translational large animal model of hibernating myocardium: characterization by serial multimodal imaging. Basic Res Cardiol 115:33. https:\/\/doi.org\/10.1007\/s00395-020-0788-0","journal-title":"Basic Res Cardiol"},{"key":"1078_CR78","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10557-018-6793-y","volume":"32","author":"A Maulik","year":"2018","unstructured":"Maulik A, Davidson SM, Piotrowska I, Walker M, Yellon DM (2018) Ischaemic preconditioning protects cardiomyocytes from anthracycline-induced toxicity via the PI3K pathway. Cardiovasc Drugs Ther 32:245\u2013253. https:\/\/doi.org\/10.1007\/s10557-018-6793-y","journal-title":"Cardiovasc Drugs Ther"},{"key":"1078_CR79","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31:63\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6711-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"1078_CR80","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/ehf2.12695","volume":"7","author":"J Meessen","year":"2020","unstructured":"Meessen J, Cardinale D, Ciceri F, Sandri MT, Civelli M, Bottazzi B, Cucchi G, Menatti E, Mangiavacchi M, Condorelli G, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Pastori P, Ghisoni F, Bianchi A, Falci C, Cortesi P, Farolfi A, Monopoli A, Milandri C, Bregni M, Malossi A, Nassiacos D, Verusio C, Staszewsky L, Leone R, Novelli D, Balconi G, Nicolis EB, Franzosi MG, Masson S, Garlanda C, Mantovani A, Cipolla CM, Latini R, Investigators I-OS (2020) Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. ESC Heart Fail 7:1452\u20131466. https:\/\/doi.org\/10.1002\/ehf2.12695","journal-title":"ESC Heart Fail"},{"key":"1078_CR81","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne D, Butruille L, Staels B (2021) PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol 18:809\u2013823. https:\/\/doi.org\/10.1038\/s41569-021-00569-6","journal-title":"Nat Rev Cardiol"},{"key":"1078_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.847012","author":"MB Morelli","year":"2022","unstructured":"Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, D\u2019Uva G (2022) Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2022.847012","journal-title":"Front Cardiovasc Med"},{"key":"1078_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3395","author":"A Moreno-Arciniegas","year":"2024","unstructured":"Moreno-Arciniegas A, Lopez A, Kelm M, D\u2019Amore F, Gomes da Silva M, Sanchez-Gonzalez J, Lopez-Fernandez T, Cordoba R, Asteggiano R, Camus V, Smink J, Ferrerira A, Kersten MJ, Bola\u00f1os N, Escalera N, Pacella E, Gomez-Talavera S, Quesada AJ, Rossello X, Ibanez B (2024) Rationale and design of RESILIENCE: a prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3395","journal-title":"Eur J Heart Fail"},{"key":"1078_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12277","author":"F Muehlberg","year":"2018","unstructured":"Muehlberg F, Funk S, Zange L, von Knobelsdorff-Brenkenhoff F, Blaszczyk E, Schulz A, Ghani S, Reichardt A, Reichardt P, Schulz-Menger J (2018) Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.12277","journal-title":"ESC Heart Fail"},{"key":"1078_CR85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1074248418821721","volume":"24","author":"M Nabati","year":"2019","unstructured":"Nabati M, Janbabai G, Esmailian J, Yazdani J (2019) Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther 24:233\u2013241. https:\/\/doi.org\/10.1177\/1074248418821721","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1078_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocmr.2024.101033","author":"K Nakata","year":"2024","unstructured":"Nakata K, Kucukseymen S, Cai X, Yankama T, Rodriguez J, Sai E, Pierce P, Ngo L, Nakamori S, Tung N, Manning WJ, Nezafat R (2024) Cardiovascular magnetic resonance characterization of myocardial tissue injury in a miniature swine model of cancer therapy-related cardiovascular toxicity. J Cardiovasc Magn Reson. https:\/\/doi.org\/10.1016\/j.jocmr.2024.101033","journal-title":"J Cardiovasc Magn Reson"},{"key":"1078_CR87","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","volume":"330","author":"TG Neilan","year":"2023","unstructured":"Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, Smith A, Heemelaar JC, Brahmbhatt P, Ho JS, Sama S, Svoboda J, Neuberg DS, Abramson JS, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Soumerai JD, Han Y, Friedman RS, Lacasce AS, Ky B, Landsburg D, Nasta S, Kwong RY, Jerosch-Herold M, Redd RA, Hua L, Januzzi JL, Asnani A, Mousavi N, Scherrer-Crosbie M (2023) Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA 330:528\u2013536. https:\/\/doi.org\/10.1001\/jama.2023.11887","journal-title":"JAMA"},{"key":"1078_CR88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00395-023-01006-0","volume":"118","author":"FS Nettersheim","year":"2023","unstructured":"Nettersheim FS, Schluter JD, Kreuzberg W, Mehrkens D, Grimm S, Nemade H, Braumann S, Hof A, Guthoff H, Peters V, Hoyer FF, Kargapolova Y, Lackmann JW, Muller S, Pallasch CP, Hallek M, Sachinidis A, Adam M, Winkels H, Baldus S, Geissen S, Mollenhauer M (2023) Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy. Basic Res Cardiol 118:36. https:\/\/doi.org\/10.1007\/s00395-023-01006-0","journal-title":"Basic Res Cardiol"},{"key":"1078_CR89","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/hearts5010005","volume":"5","author":"HC Nguyen","year":"2024","unstructured":"Nguyen HC, Frisbee JC, Singh KK (2024) Different mechanisms in doxorubicin-induced cardiomyopathy: impact of BRCA1 and BRCA2 mutations. Hearts 5:54\u201374. https:\/\/doi.org\/10.3390\/hearts5010005","journal-title":"Hearts"},{"key":"1078_CR90","doi-asserted-by":"publisher","first-page":"6534","DOI":"10.1111\/jcmm.15305","volume":"24","author":"N Osataphan","year":"2020","unstructured":"Osataphan N, Phrommintikul A, Chattipakorn SC, Chattipakorn N (2020) Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions. J Cell Mol Med 24:6534\u20136557. https:\/\/doi.org\/10.1111\/jcmm.15305","journal-title":"J Cell Mol Med"},{"key":"1078_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.02.006","author":"M Ozcan","year":"2023","unstructured":"Ozcan M, Guo Z, Valenzuela Ripoll C, Diab A, Picataggi A, Rawnsley D, Lotfinaghsh A, Bergom C, Szymanski J, Hwang D, Asnani A, Kosiborod M, Zheng J, Hayashi RJ, Woodard PK, Kovacs A, Margulies KB, Schilling J, Razani B, Diwan A, Javaheri A (2023) Sustained alternate-day fasting potentiates doxorubicin cardiotoxicity. Cell Metab. https:\/\/doi.org\/10.1016\/j.cmet.2023.02.006","journal-title":"Cell Metab"},{"key":"1078_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23041","author":"G Pakravan","year":"2022","unstructured":"Pakravan G, Peymani M, Abedpoor N, Safaeinejad Z, Yadegari M, Derakhshan M, Nasr Esfahani MH, Ghaedi K (2022) Antiapoptotic and anti-inflammatory effects of Ppargamma agonist, pioglitazone, reversed Dox-induced cardiotoxicity through mediating of miR-130a downregulation in C57BL\/6 mice. J Biochem Mol Toxicol. https:\/\/doi.org\/10.1002\/jbt.23041","journal-title":"J Biochem Mol Toxicol"},{"key":"1078_CR93","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mito.2016.07.005","volume":"30","author":"GC Pereira","year":"2016","unstructured":"Pereira GC, Pereira SP, Tavares LC, Carvalho FS, Magalhaes-Novais S, Barbosa IA, Santos MS, Bjork J, Moreno AJ, Wallace KB, Oliveira PJ (2016) Cardiac cytochrome c and cardiolipin depletion during anthracycline-induced chronic depression of mitochondrial function. Mitochondrion 30:95\u2013104. https:\/\/doi.org\/10.1016\/j.mito.2016.07.005","journal-title":"Mitochondrion"},{"key":"1078_CR94","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","volume":"4","author":"C Porter","year":"2022","unstructured":"Porter C, Azam TU, Mohananey D, Kumar R, Chu J, Lenihan D, Dent S, Ganatra S, Beasley GS, Okwuosa T (2022) Permissive cardiotoxicity: the clinical crucible of cardio-oncology. JACC CardioOncol 4:302\u2013312. https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.005","journal-title":"JACC CardioOncol"},{"key":"1078_CR95","doi-asserted-by":"publisher","first-page":"1242596","DOI":"10.3389\/fcvm.2023.1242596","volume":"10","author":"Y Qiu","year":"2023","unstructured":"Qiu Y, Jiang P, Huang Y (2023) Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention. Front Cardiovasc Med 10:1242596. https:\/\/doi.org\/10.3389\/fcvm.2023.1242596","journal-title":"Front Cardiovasc Med"},{"key":"1078_CR96","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/cvr\/cvx017","volume":"113","author":"J Ritterhoff","year":"2017","unstructured":"Ritterhoff J, Tian R (2017) Metabolism in cardiomyopathy: every substrate matters. Cardiovasc Res 113:411\u2013421. https:\/\/doi.org\/10.1093\/cvr\/cvx017","journal-title":"Cardiovasc Res"},{"key":"1078_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01062-0","author":"SA Sabe","year":"2024","unstructured":"Sabe SA, Harris DD, Broadwin M, Sellke FW (2024) Cardioprotection in cardiovascular surgery. Basic Res Cardiol. https:\/\/doi.org\/10.1007\/s00395-024-01062-0","journal-title":"Basic Res Cardiol"},{"key":"1078_CR98","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jaccao.2023.08.003","volume":"5","author":"FN Salloum","year":"2023","unstructured":"Salloum FN, Tocchetti CG, Ameri P, Ardehali H, Asnani A, de Boer RA, Burridge P, Cabrera JA, de Castro J, Cordoba R, Costa A, Dent S, Engelbertsen D, Fernandez-Velasco M, Fradley M, Fuster JJ, Galan-Arriola C, Garcia-Lunar I, Ghigo A, Gonzalez-Neira A, Hirsch E, Ibanez B, Kitsis RN, Konety S, Lyon AR, Martin P, Mauro AG, Mazo Vega MM, Meijers WC, Neilan TG, Rassaf T, Ricke-Hoch M, Sepulveda P, Thavendiranathan P, van der Meer P, Fuster V, Ky B, Lopez-Fernandez T, International Cardio-Oncology S (2023) Priorities in cardio-oncology basic and translational science: GCOS 2023 symposium proceedings: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 5:715\u2013731. https:\/\/doi.org\/10.1016\/j.jaccao.2023.08.003","journal-title":"JACC CardioOncol"},{"key":"1078_CR99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12968-015-0116-2","volume":"17","author":"J Sanchez-Gonzalez","year":"2015","unstructured":"Sanchez-Gonzalez J, Fernandez-Jimenez R, Nothnagel ND, Lopez-Martin G, Fuster V, Ibanez B (2015) Optimization of dual-saturation single bolus acquisition for quantitative cardiac perfusion and myocardial blood flow maps. J Cardiovasc Magn Reson 17:21. https:\/\/doi.org\/10.1186\/s12968-015-0116-2","journal-title":"J Cardiovasc Magn Reson"},{"key":"1078_CR100","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146076","author":"S Sano","year":"2021","unstructured":"Sano S, Wang Y, Ogawa H, Horitani K, Sano M, Polizio AH, Kour A, Yura Y, Doviak H, Walsh K (2021) TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.146076","journal-title":"JCI Insight"},{"key":"1078_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132000","author":"L Schirone","year":"2022","unstructured":"Schirone L, D\u2019Ambrosio L, Forte M, Genovese R, Schiavon S, Spinosa G, Iacovone G, Valenti V, Frati G, Sciarretta S (2022) Mitochondria and doxorubicin-induced cardiomyopathy: a complex interplay. Cells. https:\/\/doi.org\/10.3390\/cells11132000","journal-title":"Cells"},{"key":"1078_CR102","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1600-0773.1996.tb00222.x","volume":"78","author":"J Schjott","year":"1996","unstructured":"Schjott J, Olsen H, Berg K, Jynge P (1996) Pretreatment with ischaemia attenuates acute epirubicin-induced cardiotoxicity in isolated rat hearts. Pharmacol Toxicol 78:381\u2013386. https:\/\/doi.org\/10.1111\/j.1600-0773.1996.tb00222.x","journal-title":"Pharmacol Toxicol"},{"key":"1078_CR103","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jjcc.2022.01.001","volume":"80","author":"K Shinlapawittayatorn","year":"2022","unstructured":"Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N (2022) The effects of doxorubicin on cardiac calcium homeostasis and contractile function. J Cardiol 80:125\u2013132. https:\/\/doi.org\/10.1016\/j.jjcc.2022.01.001","journal-title":"J Cardiol"},{"key":"1078_CR104","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.yjmcc.2018.10.007","volume":"124","author":"R Song","year":"2018","unstructured":"Song R, Yang Y, Lei H, Wang G, Huang Y, Xue W, Wang Y, Yao L, Zhu Y (2018) HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving alpha-tubulin acetylation. J Mol Cell Cardiol 124:58\u201369. https:\/\/doi.org\/10.1016\/j.yjmcc.2018.10.007","journal-title":"J Mol Cell Cardiol"},{"key":"1078_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107790","author":"X Sun","year":"2023","unstructured":"Sun X, Chen H, Gao R, Huang Y, Qu Y, Yang H, Wei X, Hu S, Zhang J, Wang P, Zou Y, Hu K, Ge J, Sun A (2023) Mitochondrial transplantation ameliorates doxorubicin-induced cardiac dysfunction via activating glutamine metabolism. iScience. https:\/\/doi.org\/10.1016\/j.isci.2023.107790","journal-title":"iScience"},{"key":"1078_CR106","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869\u20132879. https:\/\/doi.org\/10.1002\/cncr.11407","journal-title":"Cancer"},{"key":"1078_CR107","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318\u20131332. https:\/\/doi.org\/10.1200\/JCO.1997.15.4.1318","journal-title":"J Clin Oncol"},{"key":"1078_CR108","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132747","author":"T Tadokoro","year":"2020","unstructured":"Tadokoro T, Ikeda M, Ide T, Deguchi H, Ikeda S, Okabe K, Ishikita A, Matsushima S, Koumura T, Yamada KI, Imai H, Tsutsui H (2020) Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.132747","journal-title":"JCI Insight"},{"key":"1078_CR109","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/ehf2.14466","volume":"10","author":"M Tajstra","year":"2023","unstructured":"Tajstra M, Dyrbus M, Rutkowski T, Skladowski K, Sosnowska-Pasiarska B, Gozdz S, Radecka B, Staszewski M, Majsnerowska A, Myrda K, Nowowiejska-Wiewiora A, Skoczylas I, Rymkiewicz I, Niklewski T, Nowak J, Przybylowski P, Gasior M, Jarzab M (2023) Sacubitril\/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial. ESC Heart Fail 10:3174\u20133183. https:\/\/doi.org\/10.1002\/ehf2.14466","journal-title":"ESC Heart Fail"},{"key":"1078_CR110","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cts.12857","volume":"14","author":"M Tantawy","year":"2021","unstructured":"Tantawy M, Pamittan FG, Singh S, Gong Y (2021) Epigenetic changes associated with anthracycline-induced cardiotoxicity. Clin Transl Sci 14:36\u201346. https:\/\/doi.org\/10.1111\/cts.12857","journal-title":"Clin Transl Sci"},{"key":"1078_CR111","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvad031","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, Huang F, Shalmon T, Thorpe KE, Pezo RC, Prica A, Maze D, Abdel-Qadir H, Connelly K, Chan J, Billia F, Power C, Hanneman K, Wintersperger BJ, Brezden-Masley C, Amir E (2023) Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad031","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1078_CR112","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","volume":"9","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, Huang F, Shalmon T, Thorpe KE, Pezo RC, Prica A, Maze D, Abdel-Qadir H, Connelly KA, Chan J, Billia F, Power C, Hanneman K, Wintersperger BJ, Brezden-Masley C, Amir E (2023) Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother 9:515\u2013525. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad031","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1078_CR113","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0140-6736(13)61450-6","volume":"382","author":"M Thielmann","year":"2013","unstructured":"Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhauser M, Peters J, Jakob H, Heusch G (2013) Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382:597\u2013604. https:\/\/doi.org\/10.1016\/S0140-6736(13)61450-6","journal-title":"Lancet"},{"key":"1078_CR114","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00395-023-01009-x","volume":"118","author":"AS Titus","year":"2023","unstructured":"Titus AS, Sung EA, Zablocki D, Sadoshima J (2023) Mitophagy for cardioprotection. Basic Res Cardiol 118:42. https:\/\/doi.org\/10.1007\/s00395-023-01009-x","journal-title":"Basic Res Cardiol"},{"key":"1078_CR115","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022110632","author":"SX Van Ravenstein","year":"2022","unstructured":"Van Ravenstein SX, Mehta KP, Kavlashvili T, Byl JAW, Zhao R, Osheroff N, Cortez D, Dewar JM (2022) Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms. EMBO J. https:\/\/doi.org\/10.15252\/embj.2022110632","journal-title":"EMBO J"},{"key":"1078_CR116","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0116","author":"T Wai","year":"2015","unstructured":"Wai T, Garcia-Prieto J, Baker MJ, Merkwirth C, Benit P, Rustin P, Ruperez FJ, Barbas C, Ibanez B, Langer T (2015) Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice. Science. https:\/\/doi.org\/10.1126\/science.aad0116","journal-title":"Science"},{"key":"1078_CR117","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cstres.2024.03.003","volume":"29","author":"T Wang","year":"2024","unstructured":"Wang T, Xing G, Fu T, Ma Y, Wang Q, Zhang S, Chang X, Tong Y (2024) Role of mitochondria in doxorubicin-mediated cardiotoxicity: from molecular mechanisms to therapeutic strategies. Cell Stress Chaperones 29:349\u2013357. https:\/\/doi.org\/10.1016\/j.cstres.2024.03.003","journal-title":"Cell Stress Chaperones"},{"key":"1078_CR118","doi-asserted-by":"publisher","first-page":"11087","DOI":"10.3390\/ijms160511087","volume":"16","author":"Z Wang","year":"2015","unstructured":"Wang Z, Wang J, Xie R, Liu R, Lu Y (2015) Mitochondria-derived reactive oxygen species play an important role in Doxorubicin-induced platelet apoptosis. Int J Mol Sci 16:11087\u201311100. https:\/\/doi.org\/10.3390\/ijms160511087","journal-title":"Int J Mol Sci"},{"key":"1078_CR119","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.122.062166","volume":"148","author":"WD Watson","year":"2023","unstructured":"Watson WD, Green PG, Lewis AJM, Arvidsson P, De Maria GL, Arheden H, Heiberg E, Clarke WT, Rodgers CT, Valkovic L, Neubauer S, Herring N, Rider OJ (2023) Retained metabolic flexibility of the failing human heart. Circulation 148:109\u2013123. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062166","journal-title":"Circulation"},{"key":"1078_CR120","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaccao.2023.08.008","volume":"5","author":"RL Wilson","year":"2023","unstructured":"Wilson RL, Christopher CN, Yang EH, Barac A, Adams SC, Scott JM, Dieli-Conwright CM (2023) Incorporating exercise training into cardio-oncology care: current evidence and opportunities: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 5:553\u2013569. https:\/\/doi.org\/10.1016\/j.jaccao.2023.08.008","journal-title":"JACC CardioOncol"},{"key":"1078_CR121","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","volume":"51","author":"N Yamaguchi","year":"2015","unstructured":"Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH (2015) Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer 51:2314\u20132320. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.031","journal-title":"Eur J Cancer"},{"key":"1078_CR122","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbcan.2013.12.002","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang F, Teves SS, Kemp CJ, Henikoff S (2014) Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845:84\u201389. https:\/\/doi.org\/10.1016\/j.bbcan.2013.12.002","journal-title":"Biochim Biophys Acta"},{"key":"1078_CR123","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00395-023-00992-5","volume":"118","author":"DM Yellon","year":"2023","unstructured":"Yellon DM, Beikoghli Kalkhoran S, Davidson SM (2023) The RISK pathway leading to mitochondria and cardioprotection: how everything started. Basic Res Cardiol 118:22. https:\/\/doi.org\/10.1007\/s00395-023-00992-5","journal-title":"Basic Res Cardiol"},{"key":"1078_CR124","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00018-024-05169-4","volume":"81","author":"P Zhao","year":"2024","unstructured":"Zhao P, Li Y, Xu X, Yang H, Li X, Fu S, Guo Z, Zhang J, Li H, Tian J (2024) Neutrophil extracellular traps mediate cardiomyocyte ferroptosis via the Hippo-Yap pathway to exacerbate doxorubicin-induced cardiotoxicity. Cell Mol Life Sci 81:122. https:\/\/doi.org\/10.1007\/s00018-024-05169-4","journal-title":"Cell Mol Life Sci"}],"container-title":["Basic Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-024-01078-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00395-024-01078-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-024-01078-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:08:20Z","timestamp":1738573700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00395-024-01078-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1007\/s00395-024-01078-6","relation":{},"ISSN":["1435-1803"],"issn-type":[{"value":"1435-1803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}